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the second group in public sector was cephalosporins (4%) and in private sector were 
penicillins (3%). In private sector pediatricians prescribed antibiotics to 52% (17/33) 
of children with diarrhea and ﬂ uoroquinolone group was prescribed to all. At public 
facilities, main members from ﬂ uoroquinolones were norﬂ oxacin, followed by oﬂ oxa-
cin and ciproﬂ oxacin. At private clinics, it was oﬂ oxacin followed by ciproﬂ oxacin. 
Pediatricians mainly prescribed oﬂ oxacin, followed by norﬂ oxacin. CONCLUSIONS: 
This study clearly shows over-prescription and irrational use of antibiotics for treat-
ment of diarrhea that warrants interventional strategies. 
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OBJECTIVES: To analyze the pattern of non-prescription medicine purchase by 
consumer from community pharmacies in Malaysia. METHODS: A cross-sectional 
survey comprised a sample of 1799 community pharmacy consumers was conducted 
nationwide. A pharmacy “exit survey” was developed and administered to pharmacy 
consumers of randomly selected community pharmacies in order to collect information 
on the purchased nonprescription medicine(s) including its costs. In this study, the 
nonprescription medicine deﬁ nition was adopted from the Malaysian Poison Act 
1952. Data were analyzed using Kruskal–Wallis, Mann–Whitney, chi-square and 
Spearman correlation test in SPSS v15. RESULTS: A total of 2175 nonprescription 
medicines were purchased by consumers interviewed in 2 weeks study period. The 
total cost estimated for all item purchased was RM41,000 (USD13,000). About 
39.6% of the purchased items are listed under scheduled poison, 45.5% were unsched-
uled poison and 12.5% are those listed as traditional and complementary medicine. 
Medicine for alimentary tract and metabolism, musculo-skeletal system and respira-
tory system as categorized by Anatomical Therapeutic Coding were among the highest 
purchased medicine. Factors such as gender especially females, area of origin especially 
those from urban area, ethnicity especially chinese consumers and those earning high 
income level shows to have a signiﬁ cant inﬂ uence in the spending for non-prescription 
medicine purchasing. This study also showed purchasing for non-prescription medi-
cine signiﬁ cantly increased as aging. Consumers spent signiﬁ cantly more on non-
controlled medicine such as vitamins and herbal preparations compared to other 
categories of medicines (χ2 = 185.07, P < 0.001). CONCLUSIONS: The evaluation 
on pattern of nonprescription medicine purchasing in Malaysia reveals that consumers 
in Malaysia are able to spend money for buying medicines to treat minor ailments 
and practice of self-medication. The socio-demographic factors that associated with 
non-prescription medicine purchase will serve as useful information for policymakers 
and also the pharmaceutical industry for future development in rational medicine use 
education among consumers in the country. 
HEALTH CARE USE & POLICY STUDIES – Disease Management
PHP3
RARE DISEASES, ORPHAN DRUGS, AND THE LEGISLATION IN CHINA
Zhang YJ1, Guo JJ1, Wang JB2
1University of Cincinnati, Cincinnati, OH, USA; 2People’s Liberation Army 309 Hospital, 
Beijing, China
OBJECTIVES: Public awareness of rare diseases and access to orphan drugs is increas-
ing in China. The purpose of this study was to review the epidemics of rare diseases, 
the access to orphan drug treatments, and its related legislation in China. METHODS: 
A systematic literature review was performed based on published articles, government 
Websites, and some Internet search engines. The rare diseases, available orphan drug 
treatments, and related legislations in China were reviewed. Some comparisons related 
to these topics were discussed between China and developed countries like the United 
States. RESULTS: With conservative estimation, there are at least 10 million Chinese 
people living with rare diseases. The frequently mentioned rare diseases in China 
include osteogenesis imperfecta, neuromuscular diseases, Fabry disease, Gaucher 
disease, phenylketonurias, hemophilia A and B, lymphangioleiomyomatosis, albinism, 
and acromegaly. Patients with rare diseases in China generally lack the access to 
appropriate health care especially the orphan drug therapies. While we observed the 
signiﬁ cant impact of Orphan Drug Act on new drug developments and rare disease 
treatments in developed countries, there is little new orphan drug designated or devel-
oped in China. There are very few imported orphan drugs in the Chinese market. A 
grouping number of Chinese rare-disease organizations such as the China Albinism 
Association and the China-Dolls Care and Support Association are working with 
government on a new legislation about health care assesses and insurance policy for 
rare diseases. CONCLUSIONS: Public and governmental concerns about rare diseases 
have been boosted in China. Their available treatments and legislation in China are 
lagging far behind the United States, the European Union, Australia, Singapore, Japan, 
and South Korea. An effective public health insurance and public policy are needed for 
rare disease treatments and orphan drug developments. 
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OBJECTIVES: Iran had one of the highest uses of Diphenoxylate in the world in 2008. 
About 1 billion tablets of Diphenoxylate 2.5 mg have been consumed during that year. 
In the last months of 2008 the ministry of health tried some policies to reduce the 
consumption. One was rationing in production the other was doubling the price of 
10 medicines which likely were abused including Diphenoxylate. This study tries to 
show the effectiveness of these two interventions by evaluating monthly consumption 
of Diphenoxylate during recent 5 years ended to March 2010. METHODS: Data were 
gathered from the distributors and wholesalers of this medicine from whole the 
country. These data were crosschecked with importation data in the ministry of health. 
We did a time trend analysis on tabulated data. RESULTS: There are some variations 
in monthly use of Diphenoxylate but the trend shows a signiﬁ cant decrease after the 
rationing in production. In 2009 the average consumption has reached to less than 
650 millions of tablet, four Deﬁ ned Daily Dose per 1000 Inhabitants per day which 
shows 36% decrease in comparison with the previous year. In second half of 2009 
and ﬁ rst 2 months of 2010 after the second intervention, there is no signiﬁ cant change 
in the trend. CONCLUSIONS: Although the high consumption of opiates in Iran is 
a multi factorial phenomena but this study shows; the ﬁ rst intervention has been able 
to control the abuse of Diphenoxylate due to the reduction of market supply and 
decrease in Diphenoxylate’s unofﬁ cial promotion. Considerable result wasn’t seen in 
the second approach. The user price of Diphenoxylate tablet in Iran is too cheap and 
doubling the price doesn’t work at all. A signiﬁ cant tax mark-up and increasing the 
price based on label use may affect on affordability of Diphenoxylate’s abuse. 
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OBJECTIVES: In the 1980s, China launched market-oriented reforms. Public hospi-
tals were encouraged to make their own incomes with the aim of mobilizing medical 
workers and improving hospital efﬁ ciency. Less government funding resulted in deﬁ -
cits for public health institutions, which forced hospitals to generate their own revenue 
by aggressively selling drugs, especially expensive drugs. There are challenges in poor 
drug access, drug procurement, rising drug costs and ﬁ nancial risk. In March 2009, 
China ﬁ nally unveiled its health care reform plan. The Chinese government announced 
it will institute an essential medicine system within 3 years to drive down prescription 
costs and quell public complaints of limited accessibility of medicines. This study is 
to describe the strategies to build the essential medicine system at the provincial level 
in China and challenges associated with promoting it. METHODS: Key actors, their 
power, views and interactions will be assessed using appropriate qualitative methods 
as these are best suited to understanding complexity, richness of material and motiva-
tions of actors, and using a policy analysis to know the key governance issues and 
underlying relationships affecting its success or failure. RESULTS: The system includes 
a list of essential medicines that would be produced and distributed under government 
control and supervision, and it should be used at all public health facilities at grass-
roots levels from 2009. The central government will set reference prices, based on 
which, provincial governments set the purchase prices of the drugs in their jurisdiction. 
Public medical and health facilities at the grassroots levels should sell the drugs at the 
purchase prices. These generally involve the transfer for a ﬁ xed fee from the local 
MOH to the health service center/post in exchange for the removal of retail mark up, 
which couldn’t offset the proﬁ t of selling drugs. CONCLUSIONS: The provider incen-
tive is very crucial for building an essential medicine system, which is dependent upon 
the reimbursement system. 
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OBJECTIVES: The pricing system for chemical drugs is currently applied to biologics 
in China as no speciﬁ c pricing system for biologics exists yet in China. This practice 
does not fully reﬂ ect the characteristics of biologics and may potentially prevent the 
launch of biologics in China and discourage the development of biologics. The objec-
tive of this study is to explore adequate pricing mechanisms for biologics. METHODS: 
Both primary research (ﬁ eld research, expert interviews, surveys) and secondary 
research were conducted to determine the key determinants of the price of biologics 
and understand the complexity of R&D, manufacturing and distribution required for 
biologics. Statistical analyses were performed to assess the relationship of key deter-
minants and the price. Government and manufacturer behavior were modeled using 
game theory to demonstrate prerequisites of implementing ‘differential pricing’. 
RESULTS: A different pricing system is required for biologics given its unique char-
acteristics. Certain characteristics (including special clinical value, target-speciﬁ c R&D 
